Samenvatting
Botulinetoxine werd intussen al enige tijd geleden door een oogarts geïntroduceerd als een mogelijk therapeuticum. Intussen heeft het een plaats verworven ter behandeling van blefarospasmen, hemifaciale spasmen, spastisch entropion, protectieve ptosis, strabisme, nystagmus. Er zijn twee producten beschikbaar op de markt. Ervaringen met Botox® worden besproken.
This is a preview of subscription content, log in via an institution to check access.
Literatuur
Aoki R. A comparison of the safety margins of the botuline neurotoxin serotypes A, B and F in mice. Toxicon 2001;39:1815-20.
Hambleton P, Moore AP. Botuline neurotoxins: origin, structure, molecular actions and antibodies. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:16-27.
Jankovic J. Extent of clinical problem, measurement of clinical resistance, development of antibodies, review of assay options. Toxins 1999;1(1):4.
Nusgens Z, Roggenkamper P. Comparison of two Botuline toxin preparations in the treatment of essential blepharospasm. Graefe's Arch Clin Exp Ophthalmol 1997;235:197-9.
Boghen DR, Lesser RL. Blepharospasm and hemifacial spasm. Corporate Library 2001;389(July):1-8.
Boghen DR, Lesser RL. Blepharospasm and hemifacial spasm. Curr Treat Options Neurol 2000;2(5):393-400.
Elston JS. Idiopathic Blepharospasm, hemifacial spasm and therapeutic ptosis induction. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:90-100.
Elston JS. The clinical use of botuline toxin. Seminar in ophthalmology 1998;3(4):249-260.
Moore AP. Clinical aspects of treatment with botuline toxin. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:28-53
Osaka M, Keltner JL. Therapeutic review: Botuline A toxin in ophthalmology. Survey of Ophthalmol 1991;36(1):28-46.
Jordan DR, Patrinely JR, Anderson RL, Thiese SM. (1989). Essential blepharospasm and related dystonias. Survey of Ophthalmology 1989;34(2):123-32.
Tucha O, Naumann M, Berg D, et al. Quality of life in patients with blepharospasm. Acad Neurol Scand 2001;103(1):49-52.
Wenzel T, Schneider P, Griengl H, et al. Psychiatric disorders in patients with blepharospasm: a reactive pattern. J Psychosom Res 2000;48(6):589-91.
Aoki R. Immunologic properties of the botuline toxin serotypes. Toxins 1999;1:1-3.
Adams GGW, Kirkness CM, Lee JP. Botuline toxin A induced protective ptosis. Eye 1987;1:603-8.
Fraco MFE, Fraco MD. An evaluation of the safety and efficacy of botuline toxin type A (Botox) when used to produce a protective ptosis. Clin. Exp. Ophthalmol. 2001;29(6):394-9.
Ebner R. Botuline toxin type A in upper lid retraction of Graves’ opthalmopathy. J Clin Neurol Ophthalmol. 1993;13(4):258-61.
Kikkawa DO, Cruz RC, Christian WK, et al. Botuline A toxin injection for restrictive myopathy, thyroid related orbitopathy: effects on intraocular pressure. Am J Ophthalmol 2003;135(4):427-31.
Lee JP. Strabismus and other ocular motility disorders. In: AP Moore (ed). Handbook of botuline toxin treatment. Oxford: Blackwell Science, 1995:71-89.
Lennerstrand G, Nordbo OA, Tian S, et al. Treatment of strabismus and nystagmus with botuline toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand 1998;76(1):21-7.
Lyons CJ, Vickers SF, Lee JP. Botuline toxin therapy in dysthyroid strabismus. Eye 1990;4(4):538-42.
McNeer KW, Tucker MG, Spencer RF. Management of essential infantile esotropia with botuline toxin A: review and recommendations. J Pediatr Ophthalmol and Strab 2000;37(2):63-7.
Author information
Authors and Affiliations
Additional information
neuro-oftalmologe, Universitair Ziekenhuis Antwerpen
Rights and permissions
About this article
Cite this article
Smet, H. Botulinetoxine in de oogheelkunde. BIJB 20, 220 (2004). https://doi.org/10.1007/BF03059785
DOI: https://doi.org/10.1007/BF03059785